Platinum-Based Chemotherapy-Induced Peripheral Neuropathy Management

Overview and Clinical Characteristics

Platinum-based chemotherapy causes a dose-dependent sensory peripheral neuropathy characterized by symmetric, distal, length-dependent "glove and stocking" distribution with predominantly sensory rather than motor symptoms, affecting approximately 38% of patients receiving platinum-containing regimens and can persist lifelong in 15-40% of patients after treatment completion 1, 2
The American Society of Clinical Oncology is not mentioned in this section, however, the National Comprehensive Cancer Network recommends monitoring for neuropathy in patients receiving platinum-based chemotherapy 1, 2

The American Society of Clinical Oncology recommends duloxetine as the only evidence-based first-line treatment for painful platinum-induced peripheral neuropathy, with particularly strong efficacy for oxaliplatin-induced neuropathy compared to taxane-induced neuropathy 3, 4
Duloxetine showed 59% pain reduction versus 38% with placebo in 231 patients, with benefits including improvement in quality of life beyond pain relief, and evidence level: Level I, Grade B 3, 5
The maximum dose of duloxetine is 60 mg daily; higher doses (120 mg) show no additional benefit and increase adverse effects, and when discontinuing duloxetine, taper slowly rather than stopping abruptly to avoid withdrawal symptoms 3, 6

Pregabalin: Start at 75 mg twice daily, increase to 150 mg twice daily after 1-2 weeks, maximum 300 mg twice daily, with evidence level: Level II, Grade C for CIPN specifically, and requires at least 2 weeks at adequate dosage before evaluating efficacy 4, 5
Tricyclic Antidepressants (Nortriptyline): Target maximum dose of 100 mg/day, based on efficacy in other neuropathic pain conditions rather than CIPN-specific trials, with major limitation: Can cause significant toxicity, especially in elderly patients 3, 4
Venlafaxine: Evidence level: Level II, Grade C, shown effectiveness in a small randomized trial, but failed as a preventative agent for oxaliplatin neuropathy in larger trials 4, 7

Compounded Baclofen/Amitriptyline/Ketamine Gel: Formulation: Baclofen 10 mg, amitriptyline HCL 40 mg, ketamine 20 mg, showed improvement on CIPN-20 scores, especially the motor subscale, after 4 weeks, with evidence level: Level II, Grade C, but major limitation: Not commercially available; must be manufactured by a compounding pharmacy, and long-term safety has not been established 3, 4
Menthol Cream (1%): Apply twice daily to affected areas and corresponding spinal dermatomal regions, improvement in pain scores after 4-6 weeks, with evidence level: Level III, Grade B 4, 5
Capsaicin 8% Patches: Established efficacy for other neuropathic pain forms, effects can last up to 90 days, with evidence level: Level I, Grade C for general neuropathic pain; Level III, Grade C for CIPN, particularly useful for localized pain areas if duloxetine and pregabalin fail 4, 5

Exercise Therapy: Home-based muscle strengthening and balance exercises may provide benefit with significant reduction in neuropathic pain scores, should be recommended before and during chemotherapy for potential overall benefit, with limitation: Larger studies are needed to confirm efficacy 4
Acupuncture: Two randomized trials show conflicting results, insufficient evidence for routine recommendation outside clinical trials, may be tried based on patient preference and availability, given low risk profile 4, 6
Physical Therapy: Can help address symptoms, particularly for balance issues and fall prevention in elderly patients, with limitation: Can be limited by cost, time commitment, and patient motivation 2
Scrambler Therapy: One phase II trial showed twice as many patients had ≥50% improvement compared to TENS, another trial showed no benefit over sham treatment, evidence is mixed; further research needed 6

For Treatment: Acetyl-L-carnitine, NSAIDs and glucocorticoids, Vitamin B12, with evidence level: Inferior to duloxetine 4
For Prevention: No agents are recommended for preventing platinum-induced neuropathy, specifically avoid: Calcium/magnesium infusions, Venlafaxine, Gabapentin/pregabalin, Amifostine, glutathione, vitamin E, acetyl-L-carnitine, with evidence level: Lack sufficient evidence and have concerns about reducing chemotherapy efficacy 1, 4, 7

Clinical Assessment: Use self-reporting questionnaires dedicated to neuropathy, regularly assess for comorbidities that may worsen symptoms, monitor for fall risk, particularly in elderly patients with sensory neuropathy 2
Supportive Care Measures: Physiotherapy and physical activity, referral to podiatrists for foot care, patient education on adequate footwear to prevent injuries, support in daily activities as needed, vitamin B supplementation can be discussed, though evidence is limited 2
Specialist Referral: Refer to neurologist if neuropathy induces chronic pain requiring specialized medication management, consider referral for nerve conduction studies if diagnosis is uncertain or symptoms are atypical 1, 2